Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 16 studies | 36% ± 15% | |
peripheral blood | 15 studies | 28% ± 9% | |
kidney | 8 studies | 30% ± 5% | |
brain | 8 studies | 28% ± 9% | |
eye | 7 studies | 32% ± 13% | |
liver | 7 studies | 29% ± 20% | |
intestine | 6 studies | 29% ± 12% | |
uterus | 5 studies | 37% ± 12% | |
placenta | 4 studies | 37% ± 15% | |
bone marrow | 4 studies | 23% ± 4% | |
prostate | 4 studies | 33% ± 7% | |
lymph node | 4 studies | 32% ± 12% | |
breast | 4 studies | 36% ± 5% | |
pancreas | 3 studies | 52% ± 17% | |
adrenal gland | 3 studies | 32% ± 6% | |
esophagus | 3 studies | 45% ± 19% | |
skin | 3 studies | 32% ± 6% | |
thymus | 3 studies | 49% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 2627.46 | 258 / 258 | 100% | 35.83 | 230 / 230 |
esophagus | 100% | 2035.99 | 1445 / 1445 | 100% | 31.64 | 183 / 183 |
ovary | 100% | 1452.34 | 180 / 180 | 100% | 39.99 | 430 / 430 |
stomach | 100% | 1522.83 | 359 / 359 | 100% | 33.93 | 286 / 286 |
uterus | 100% | 1555.68 | 170 / 170 | 100% | 41.07 | 459 / 459 |
brain | 100% | 2754.80 | 2641 / 2642 | 100% | 33.97 | 705 / 705 |
intestine | 100% | 1751.41 | 966 / 966 | 100% | 32.95 | 526 / 527 |
kidney | 100% | 2126.20 | 89 / 89 | 100% | 23.59 | 899 / 901 |
lung | 100% | 2059.13 | 576 / 578 | 100% | 38.85 | 1155 / 1155 |
skin | 100% | 2077.07 | 1806 / 1809 | 100% | 36.51 | 471 / 472 |
bladder | 100% | 1912.10 | 21 / 21 | 100% | 36.48 | 502 / 504 |
liver | 100% | 1330.96 | 225 / 226 | 100% | 29.26 | 406 / 406 |
thymus | 100% | 1491.46 | 651 / 653 | 100% | 26.30 | 604 / 605 |
breast | 100% | 1996.75 | 459 / 459 | 99% | 41.32 | 1112 / 1118 |
prostate | 100% | 1562.20 | 244 / 245 | 99% | 28.64 | 498 / 502 |
pancreas | 93% | 717.10 | 306 / 328 | 99% | 26.63 | 177 / 178 |
adipose | 100% | 2265.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 36.01 | 29 / 29 |
muscle | 100% | 3517.77 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1548.22 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 35.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.87 | 1 / 1 |
blood vessel | 100% | 2243.19 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 2612.85 | 846 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 34.57 | 78 / 80 |
peripheral blood | 78% | 1263.97 | 726 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140958 | Biological process | target-directed miRNA degradation |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0031466 | Cellular component | Cul5-RING ubiquitin ligase complex |
GO_0070449 | Cellular component | elongin complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0001222 | Molecular function | transcription corepressor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ELOC |
Protein name | Elongin-C Elongin-C (EloC) (Elongin 15 kDa subunit) (RNA polymerase II transcription factor SIII subunit C) (SIII p15) (Transcription elongation factor B polypeptide 1) Elongin C |
Synonyms | TCEB1 |
Description | FUNCTION: SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex) . In embryonic stem cells, the elongin BC complex is recruited by EPOP to Polycomb group (PcG) target genes in order generate genomic region that display both active and repressive chromatin properties, an important feature of pluripotent stem cells (By similarity). .; FUNCTION: Core component of multiple cullin-RING-based ECS (ElonginB/C-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of target proteins . This includes the von Hippel-Lindau ubiquitination complex CBC(VHL) . By binding to BC-box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes . As part of a multisubunit ubiquitin ligase complex composed of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5; polyubiquitinates monoubiquitinated POLR2A . A number of ECS complexes (containing either KLHDC2, KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation . ECS(LRR1) ubiquitinates MCM7 and promotes CMG replisome disassembly by VCP and chromatin extraction during S-phase (By similarity). . |
Accessions | A0A8I5KYG1 ENST00000518127.5 [Q15369-1] ENST00000522337.5 [Q15369-1] Q15369 R4GMY8 ENST00000602840.5 ENST00000523815.5 [Q15369-1] ENST00000622804.2 [Q15369-1] ENST00000687224.1 [Q15369-1] ENST00000520210.1 [Q15369-2] ENST00000284811.12 [Q15369-1] ENST00000688584.1 [Q15369-2] ENST00000685938.1 A0A8J9AD82 ENST00000519487.6 E5RHG8 ENST00000519082.5 ENST00000520242.6 [Q15369-1] |